Literature DB >> 15889369

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection.

Brahm H Segal1, Lisa A Barnhart, Victoria L Anderson, Thomas J Walsh, Harry L Malech, Steven M Holland.   

Abstract

Chronic granulomatous disease (CGD) is characterized by life-threatening bacterial and fungal infections. Treatment with posaconazole led to a complete response in 7 of 8 patients with CGD with invasive mold infections (7 proven cases and 1 possible case) after failure or intolerance of treatment with standard antifungal agents. In this preliminary study, salvage treatment with posaconazole was safe and effective.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15889369     DOI： 10.1086/430068

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  35 in total

1.  Invasive aspergillosis in chronic granulomatous disease: report of 7 cases.

Authors:  Setareh Mamishi; Nima Parvaneh; Ali Salavati; Sina Abdollahzadeh; Mehdi Yeganeh
Journal:  Eur J Pediatr       Date:  2006-06-28       Impact factor: 3.183

Review 2.  Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.

Authors:  Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

Review 3.  Dual Invasive Infection with Phaeoacremonium parasiticum and Paraconiothyrium cyclothyrioides in a Renal Transplant Recipient: Case Report and Comprehensive Review of the Literature of Phaeoacremonium Phaeohyphomycosis.

Authors:  Marie-Alice Colombier; Alexandre Alanio; Blandine Denis; Giovanna Melica; Dea Garcia-Hermoso; Bénédicte Levy; Marie-Noëlle Peraldi; Denis Glotz; Stéphane Bretagne; Sébastien Gallien
Journal:  J Clin Microbiol       Date:  2015-04-22       Impact factor: 5.948

4.  Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole.

Authors:  S Shoham; D Ostrander; K Marr
Journal:  Transpl Infect Dis       Date:  2015-06-01       Impact factor: 2.228

5.  Genetic Susceptibility to Fungal Infections in Humans.

Authors:  Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2011-12-15

6.  A review of clinical experience with newer antifungals in children.

Authors:  Renee M Fallon; Jennifer E Girotto
Journal:  J Pediatr Pharmacol Ther       Date:  2008-07

7.  Antifungal agents in current pediatric practice.

Authors:  Cecinati Valerio; Teresa Perillo; Letizia Brescia; Fabio Giovanni Russo
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

Review 8.  Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

Authors:  Emily Zoller; Connie Valente; Kyle Baker; Michael E Klepser
Journal:  Drug Des Devel Ther       Date:  2010-11-04       Impact factor: 4.162

9.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

10.  Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis.

Authors:  Randall Hayden; Stanley Pounds; Katherine Knapp; Ruta Petraitiene; Robert L Schaufele; Tin Sein; Thomas J Walsh
Journal:  Pediatr Infect Dis J       Date:  2008-09       Impact factor: 2.129
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.